Results 151 to 160 of about 113,823 (359)

Hemoaction game: an educational step to improve hemophilia children and nurses self-efficacy

Journal of Advances in Medical Education and Professionalism, 2016
As hemophilia is a chronic bleeding disease and can interfere with daily performance of children, these children require continuous training to prevent bleeding and take timely action (1).
NOOASHIN BEHESHTIPOOR, SHIRIN GHANAVATI, MITRA EDRAKI, MEHRAN KARIMI, SEZANEH HAGHPANAH   +4 more
doaj  

“Liver-related aspects of gene therapy for hemophilia: need for collaborations with hepatologists”: reply [PDF]

, 2023
Wolfgang Miesbach, Graham R. Foster, Flora Peyvandi   +2 more
openalex   +1 more source

Quality of Life and Treatment Satisfaction in People With Haemophilia on Fitusiran Prophylaxis: Evidence From a Subset of ATLAS‐OLE Trial Participants Mainly From India

Haemophilia, EarlyView.
Alok Srivastava, Savita Rangarajan, Cecil Ross, Shariq Ali, Shauna Andersson, Laurel A. Menapace, Marja Puurunen, Marion Afonso   +7 more
wiley   +1 more source

Monitoring of Nonacog Beta Pegol: One‐Stage Clotting Assay With Kaolin Reagent as a Practical Alternative to Chromogenic Methods

Haemophilia, EarlyView.
ABSTRACT Introduction Accurate monitoring of nonacog beta pegol (N9‐GP) is essential to ensure appropriate treatment and to avoid under‐ or overdosing, which may result in clinical complications. The product's extended half‐life, achieved through molecular modification, poses challenges for activity measurement, particularly when using a one‐stage ...
Marie Prudková, Petr Smejkal, Dagmar Chytrá, Jiřina Zavřelová, Gabriela Romanová, Miroslav Penka, Alena Buliková   +6 more
wiley   +1 more source

INDUCTION OF TOLERANCE BY ORAL ADMINISTRATION OF FACTOR VIII AND TREATMENT OF HEMOPHILA [PDF]

, 2011
Disclosed herein is a simple method for the treatment of antigen-deficiency diseases, by orally administering to a Subject a therapeutically effective amount of the deficient anti gen, wherein the antigen is not present in a liposome.
Alpan, Oral, Kamala, Tirumalai, Matzinger, Polly, Velander, William Hugold   +3 more
core   +1 more source

Bleeding-Coagulation System Disorders and Retina (Disseminated Intravascular Coagulopathy, Von Willebrand Disease, Vitamin K Deficiency, Hemophilia A and Hemophilia B)

, 2022
BOZKURT, Erdinç, LİMON, Utku, ÖZSOY SAYGIN, Işılay   +2 more
openalex   +1 more source

Supporting Patient‐Centred Decisions on Gene Therapy for Haemophilia A: A Conceptual Model

Haemophilia, EarlyView.
Giovanni Di Minno, Sarah Bigi, Serena Barello, Enrico Ferri Grazzi, Marco Follino, Maria Francesca Mansueto, Mariasanta Napolitano, Rita Carlotta Santoro, Giancarlo Castaman   +8 more
wiley   +1 more source

In Silico Assessment of Limited Blood Sampling Strategies for Individualised Pharmacokinetic‐guided Dosing of Efanesoctocog Alfa in Haemophilia A Patients

Haemophilia, EarlyView.
ABSTRACT Introduction Efanesoctocog alfa is a novel factor VIII (FVIII) concentrate with a unique molecular design that enables Von Willebrand Factor‐independent clearance in patients with haemophilia A. Limited sampling strategies (LSSs) are necessary to implement accurate pharmacokinetic (PK)‐guided dosing for efanesoctocog alfa in clinical practice.
Jelien den Hollander, Marjon H. Cnossen, Ron A. A. Mathôt   +2 more
wiley   +1 more source

Patient and Caregiver Preferences for Long‐Term Prophylactic Treatment of Bleeds in Haemophilia: A Discrete‐Choice Experiment

Haemophilia, EarlyView.
ABSTRACT Introduction The expansion of haemophilia treatment to include non‐factor prophylaxis provides new options with various benefits, risks, administration modes, and device types, necessitating trade‐offs in decision‐making. Aim This study evaluated prophylactic treatment preferences of people with haemophilia and their caregivers, assessing ...
Hui Lu, Travis Gould, Carmine Colavecchia, Joshua Coulter, Lisa J. Wilcox, Joseph C. Cappelleri, Stephanie A. Christopher, Alexis Sohn, Brett Hauber, Álvaro A. Gutiérrez‐Vargas, Nicola Dunn, Pratima Chowdary, Jennifer A. Whitty   +12 more
wiley   +1 more source

Delivery of human apolipoprotein (apo) E to liver by an [E1(-), E3(-), polymerase(-), pTP(-)] adenovirus vector containing a liver-specific promoter inhibits atherogenesis in immunocompetent apoE-deficient mice [PDF]

, 2006
Recombinant adenovirus (rAd)-mediated apoE gene transfer to the liver of apoE(-/-) mice is anti-atherogenic. However, first generation rAd vectors were associated with immune clearance of transduced hepatocytes, while an improved [E1(-), E3(-) polymerase(
Amalfitano, A, Dickson, G, Graham, IR, Harris, JD, Owen, JS   +4 more
core